Wish to keep on prime of the science and politics driving biotech immediately? Join to get our biotech e-newsletter in your inbox.
Good morning. At first of this week, certainly one of my colleagues lamented that we weren’t seeing the flood of stories we’d usually anticipate round this time of 12 months. It appears he could have spoken too quickly — let’s get into all of the information we now have this morning.
The necessity-to-know this morning
- Belgian agency Galapagos NV stated it might break up itself into two firms, with the brand-name biotech aiming to prioritize its oncology efforts. The opposite firm, an as-yet-to-be-named department now generally known as SpinCo, plans to construct up a pipeline via transactions. SpinCo was established with about $2.5 billion in money from Galapagos.
- Sana Biotechnology reported very early information on a probably healing remedy for Kind 1 diabetes.
- Jasper Therapeutics reported preliminary outcomes from a mid-stage research of its drug briquilimab in sufferers with continual hives.
- Viking Therapeutics introduced the begin of a mid-stage research of its oral weight problems remedy.
A looming patent cliff may gasoline JPM deal-making
The annual J.P. Morgan Healthcare Convention is prime time for firms to courtroom potential M&A and licensing offers. And at this 12 months’s gathering, there shall be even better stress to discover a good match, because the pharmaceutical trade faces one of many largest patent cliffs in latest historical past.
Between now and 2033, the patents on dozens of brand-name medicines together with Keytruda, Eliquis, and Jardiance will expire, with drug firms standing to lose greater than $400 billion in income. (By comparability, the final main patent cliff that hit the trade, in 2011, jeopardized round $250 billion in drug income.)
One of many main methods firms navigate a patent cliff is to amass startups and new medicine. Consequently, many specialists anticipate pharma ramping up M&A exercise in 2025, beginning on the J.P. Morgan convention subsequent week.
“I believe individuals must buckle up, as a result of it’s already twice as frothy and will get much more,” stated an legal professional who focuses on M&A.
Learn extra from STAT’s Allison DeAngelis and Adam Feuerstein.
Califf seems to be again on his time period and worries concerning the new FDA period
Departing FDA Commissioner Robert Califf sat down with STAT in a wide-ranging interview forward of the arrival of the brand new Trump administration. He defended the FDA’s file underneath his management, praised the progress that has been made in altering the best way the company regulates meals, and expressed worries concerning the influence of the approaching Trump administration.
“I’m a political appointee, and the election didn’t go as I hoped it might, and given the statements which were made by varied people who find themselves in competition for key posts, I’ve a number of cause to be involved,” he stated.
Califf additionally echoed the fears of different critics of the Trump administration, saying mind drain within the authorities was a authentic fear: “It’s already occurring. I imply, we’re seeing a rise in early retirements and lack of good individuals.”
Learn extra from STAT’s Matt Herper.
Startup launches with neuro candidates from Denali
A brand new firm known as Tenvie Therapeutics launched immediately with a number of neuroscience drug candidates acquired from Denali Therapeutics.
The startup has raised $200 million from ARCH Enterprise Companions — certainly one of Denali’s early traders — in addition to F-Prime Capital, Mubadala Capital, and others.
Tenvie’s launch highlights the concerns that startups, and neuroscience firms, specifically, should make in powerful capital markets. Whereas Tenvie is a preclinical firm for now, executives anticipate its preliminary financing will enable it to advance into human trials and collect Section 1 information, if no more. These days, increasingly biotechs are launching with drug candidates that they’ve licensed or acquired from different corporations, and quickly transferring into medical trials.
Learn extra from STAT’s Allison DeAngelis.
Medicare positive aspects benefit in negotiating on Ozempic
The FDA accepted generic variations of older GLP-1 medicine exenatide and liraglutide in November and December. Whereas these therapies don’t work in addition to semaglutide (the scientific identify of Ozempic and Wegovy), their a lot decrease prices may give Medicare leverage to push for decrease costs for semaglutide, specialists stated.
Specialists anticipate that semaglutide will to be among the many subsequent 15 medicine up for worth negotiation. Medicare will announce that checklist by Feb. 1, and the negotiated costs will take impact in 2027.
The regulation doesn’t cease Medicare from utilizing inferior medicine as comparators for negotiating costs; this system used inferior medicine as therapeutic comparators in the course of the first spherical of negotiations.
Learn extra from STAT’s John Wilkerson.
East Asians under-represented in biopharma management
From STAT’s Usha Lee McFarling: Regardless of working in excessive numbers within the biopharma trade, East Asian Individuals are absent from the highest management positions within the subject’s largest firms, based on a report being launched immediately by ELEVAATE, a non-profit devoted to advancing East Asian Individuals in biopharma.
The report analyzed publicly traded drug firms with market capitalizations of over $500 million and located that East Asians held 7% of C-suite roles amongst all firms, however among the many trade’s largest firms, they held simply 2.5% of C-suite roles, and 1.2% of board seats. (Asian Individuals make up an estimated 25% of the pharmaceutical workforce, of which ELEVAATE estimates about 7% to 13% is East Asian.)
Within the largest drug firms, solely 4 of 160 C-suite positions have been held by East Asians and none was a CEO. Of those that have been CEOs of smaller firms, half have been founders of their very own firms, a background much less widespread for white CEOs who have been extra typically chosen by boards.
The report echoes different findings about Asian Individuals inside science in recent times — notably, they obtain main analysis awards at decrease charges and are much less prone to maintain management positions in educational medication.
Extra reads
- Pfizer executives descend on Donald Trump’s Mar-a-Lago for planning assembly, Monetary Occasions
- Utilizing lab-grown human mini-brains, scientists discover hyperlinks between head trauma, herpes, and Alzheimer’s, STAT